catherine knupp  zoetis  zoetis zoetiscom uses cookies to improve your experience when browsing our website by continuing to use this site you are agreeing to their use to find out more view our cookie policy agree about uszoetis at a glance vision  mission core beliefs awards  recognition history zoetis executive teamboard committees  charters board of directors contact our directors corporate governancepolicies  procedures board committees  charters board of directors contact our directors corporate compliance company locations home  about us  zoetis executive team  zoetis executive team share share on twitter share on facebook share on linkedin share on googleplusoneshare share on email print text size  prev next  zoetis executive team catherine knupp executive vice president and president research and development dr cathy knupp is executive vice president and president of research and development at zoetis prior to that dr knupp served as vice president veterinary medicine research and development at pfizer animal health a position she held since  in her role she is responsible for managing global rd activities in support of discovering and registering medicines and vaccines to prevent disease in companion animals and livestock species and improve health and optimize performance prior to joining pfizer animal health dr knupp led pfizers michigan laboratories in pharmacokinetics dynamics and metabolism and chaired the midwest exploratory development management team in pfizer global research and development she began her career in  at bristolmyers squibb where she held positions of increasing responsibility in drug metabolism and pharmacokinetics this experience led to her appointment as executive director drug metabolism and pharmacokinetics her last position with that company was as vice president chemical manufacturing controls cmc where she was responsible for global cmc regulatory submissions dr knupp earned her doctor of veterinary medicine dvm degree in  from the university of illinois where she also received a masters degree in toxicology and a bachelors degree in veterinary biosciences she also earned another bachelors degree in chemistry from western illinois university about us see zoetis at a glancemore select a country zoetiscom zoetiszocom argentina australia austria belgium french belgium dutch brazil bolivia bulgaria canada chile china colombia costa rica croatia czech republic ecuador egypt estonia finland france germany greece hungary india indonesia ireland israel italy japan latvia lithuania malaysia mexico morocco netherlands new zealand paraguay peru philippines poland portugal romania russia serbia slovakia slovenia south africa south korea spain switzerland taiwan thailand turkey ukraine united kingdom united states uruguay vietnam you are leaving the country website to access another site in the group regulatory constraints and medical practices vary from country to country consequently the information provided on the site in which you enter may not be suitable for use in your country home sitemap privacy policy cookie policy terms of use catherine knupp  zoetis  zoetis zoetiscom uses cookies to improve your experience when browsing our website by continuing to use this site you are agreeing to their use to find out more view our cookie policy agree about uszoetis at a glance vision  mission core beliefs awards  recognition history zoetis executive teamboard committees  charters board of directors contact our directors corporate governancepolicies  procedures board committees  charters board of directors contact our directors corporate compliance company locations home  about us  zoetis executive team  zoetis executive team share share on twitter share on facebook share on linkedin share on googleplusoneshare share on email print text size  prev next  zoetis executive team catherine knupp executive vice president and president research and development dr cathy knupp is executive vice president and president of research and development at zoetis prior to that dr knupp served as vice president veterinary medicine research and development at pfizer animal health a position she held since  in her role she is responsible for managing global rd activities in support of discovering and registering medicines and vaccines to prevent disease in companion animals and livestock species and improve health and optimize performance prior to joining pfizer animal health dr knupp led pfizers michigan laboratories in pharmacokinetics dynamics and metabolism and chaired the midwest exploratory development management team in pfizer global research and development she began her career in  at bristolmyers squibb where she held positions of increasing responsibility in drug metabolism and pharmacokinetics this experience led to her appointment as executive director drug metabolism and pharmacokinetics her last position with that company was as vice president chemical manufacturing controls cmc where she was responsible for global cmc regulatory submissions dr knupp earned her doctor of veterinary medicine dvm degree in  from the university of illinois where she also received a masters degree in toxicology and a bachelors degree in veterinary biosciences she also earned another bachelors degree in chemistry from western illinois university about us see zoetis at a glancemore select a country zoetiscom zoetiszocom argentina australia austria belgium french belgium dutch brazil bolivia bulgaria canada chile china colombia costa rica croatia czech republic ecuador egypt estonia finland france germany greece hungary india indonesia ireland israel italy japan latvia lithuania malaysia mexico morocco netherlands new zealand paraguay peru philippines poland portugal romania russia serbia slovakia slovenia south africa south korea spain switzerland taiwan thailand turkey ukraine united kingdom united states uruguay vietnam you are leaving the country website to access another site in the group regulatory constraints and medical practices vary from country to country consequently the information provided on the site in which you enter may not be suitable for use in your country home sitemap privacy policy cookie policy terms of use catherine knupp zoetis inc evp  president research  development  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   catherine knupp evp  president research  development zoetis inc email realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for catherine knupp at zoetis inc catherine knupp works as evp  president research  development  acting in a executive management role  zoetis inc is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more executive management leads or mediamarketing prospecting automation start a free trial now recent related news  zoetis receives european commission marketing authorization for cytopoint® lokivetmab  we are honored to be granted the first approval of a monoclonal antibody therapy for veterinary use by the european commission said dr catherine knupp executive vice president and president research and development at zoetis as the first such therapy to provide relief from atopic dermatitis we are once again using our science and focus on our customers most pressing challenges to find solutions for an area of unmet need in animal health people in this article catherine knupp  first veterinary monoclonal antibody receives eu approval  manufactured by zoetis the antibody targets and neutralises canine interleukin cil a key protein involved in triggering itch in dogs “we are honoured to be granted the first approval of a monoclonal antibody therapy for veterinary use by the european commission” said dr catherine knupp executive vice president and president research and development at zoetis “as the first such therapy to provide relief from atopic dermatitis we are once again using our science and focus on our customers’ most pressing challenges to find solutions for an area of unmet need in animal health people in this article catherine knupp learn more about catherine knupp and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about catherine knupp and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved catherine knupp  zoetis inc  zoominfocom catherine a knupp of zoetis inc executive profile   welcome company news company site premium log in membership home portfolio stocks bonds funds etfs cef markets tools real life finance discuss investing ideas fund analyst picks picks by category fund pick performance picks  pans enewsletter fund spy column fund spy book bond squad fund video reports fundinvestor newsletter etf investing fund family experts fund reports all fund analyst reports fund stewardship reports fund ratings highestrated value highestrated growth highestrated largecap highestrated midcap highestrated smallcap foreign fund standouts star rating performance rating methodology fund performance top month performers top ytd performers top year performers top year performers top year performers fund category returns biggest daily nav changes closedend funds exchangetraded funds quarterly market outlook fund screeners basic screeners fund screener longterm winners solid smallgrowth funds conservative bond funds premium screeners premium fund screener index funds hidden gems lowerrisk foreign funds video center zoetis inc  zts add to portfolioget email alertsprint this pagepdf reportdata questionquotechartstock analysisperformancekey ratiosfinancialsvaluationinsidersownershipfilingsbondsoverviewexecutive compensationinsider activitykey executivesboard of directorscommittees key executives  catherine a knupp catherine a knupp executive vice president and president research and development profile connections biography dr knupp has served as our executive vice president and president of research and development since october  and was vice president of pfizers veterinary medicine research and development business unit from  to  dr knupp joined pfizer in july  and held various positions including vice president of pfizers michigan laboratories for pharmacokinetics dynamics and metabolism board membership catherine a knupp is not a member of any boards   we value your feedback let us know what you think site directory site map our products corrections help advertising opportunities licensing opportunities glossary rss mobile portfolio affiliate careers international sites australia canada china france germany hong kong italy the netherlands norway spain uk switzerland stocks by name  ticker  star rating  market cap  stock type  sector  industry mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name etfs by star rating  category  total assets  symbol  ticker  name articles by title  date  author  collection  interest  popularity investment categories by topic  sector  key indicators  user interest  market cap  industry premium stocks by name  ticker  star rating  market cap  stock type  sector  industry premium mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name premium etfs by star rating  category  total assets  symbol  ticker  name popular articles by title  date  author  collection  interest  popularity popular investment categories by topic  sector  key indicators  user interest  market cap  industry independent insightful trusted morningstar provides stock market analysis equity mutual fund and etf research ratings and picks portfolio tools and option hedge fund ira k and  plan research our reliable data and analysis can help both experienced enthusiasts and newcomers  copyright morningstar inc all rights reserved please read our terms of useand privacy policydow jones industrial average sp  nasdaq and morningstar index market barometer quotes are realtime russell  quote is  minutes delayed catherine knupp   facebook facebook？english us한국어français francebahasa indonesiapolskiespañolportuguês brasildeutschitalianomessengerfacebook liteinstagramcookie facebook   zoetis inc nysezts shares sold by boussard  gavaudan investment management llp  daily political home aboutcontact columnists privacy policy headlines politics nation world issues economy finance zoetis inc  get news  ratings daily enter your email address below to get the latest news and analysts ratings for zoetis inc with our free daily email newsletter follow dailypolitical     latest news saga communications inc nysemktsga downgraded by valuengine vale sa nysevale earns “hold” rating from jefferies group llc mastercard incorporated nysema price target raised to  united bank inc boosts stake in hollyfrontier corporation nysehfc healthcare services group inc nasdaqhcsg raised to “buy” at zacks investment research zoetis inc nysezts shares sold by boussard  gavaudan investment management llp tri pointe group inc nysetph to post q  earnings of  per share wedbush forecasts senseonics holdings inc nysesens sees large decrease in short interest stifel nicolaus reaffirms buy rating for tallgrass energy gp lp nysetegp erin energy corp nyseern sees significant drop in short interest teva pharmaceutical industries limited’s nyseteva outperform rating reaffirmed at oppenheimer holdings inc united bank inc holds stake in national fuel gas company nfg trilogy metals inc nysetmq short interest down  in june target corporation nysetgt downgraded by vetr inc boussard  gavaudan investment management llp has  million position in tiffany  co nysetif hicrush partners lp nysehclp given average rating of “buy” by analysts compass diversified holdings nysecodi earns buy rating from jefferies group llc aberdeen asset management plc lonadn lifted to buy at hsbc holdings plc mandatum life insurance co ltd sells  shares of mccormick  company incorporated nysemkc ca inc nasdaqca stake maintained by mandatum life insurance co ltd zoetis inc nysezts shares sold by boussard  gavaudan investment management llp july th    comments  filed under  by latisha jones filed under finance  sec filing articles tweet boussard  gavaudan investment management llp reduced its position in zoetis inc nysezts by  during the second quarter holdings channel reports the institutional investor owned  shares of the company’s stock after selling  shares during the period zoetis comprises about  of boussard  gavaudan investment management llp’s holdings making the stock its th largest position boussard  gavaudan investment management llp’s holdings in zoetis were worth  as of its most recent filing with the sec other institutional investors have also bought and sold shares of the company dixon hubard feinour  brown inc va raised its position in shares of zoetis by  in the second quarter dixon hubard feinour  brown inc va now owns  shares of the company’s stock valued at  after buying an additional  shares during the period ardevora asset management llp purchased a new position in shares of zoetis during the second quarter valued at about  central trust co raised its position in shares of zoetis by  in the second quarter central trust co now owns  shares of the company’s stock valued at  after buying an additional  shares during the period old national bancorp in purchased a new position in shares of zoetis during the second quarter valued at about  finally eqis capital management inc purchased a new position in shares of zoetis during the second quarter valued at about   of the stock is currently owned by institutional investors shares of zoetis inc nyse zts traded down  during midday trading on tuesday hitting  the company’s stock had a trading volume of  shares the company has a day moving average price of  and a  day moving average price of  the company has a market cap of  billion a pe ratio of  and a beta of  zoetis inc has a year low of  and a year high of  zoetis nysezts last issued its earnings results on thursday may th the company reported  eps for the quarter beating analysts’ consensus estimates of  by  zoetis had a return on equity of  and a net margin of  the business had revenue of  billion during the quarter compared to analyst estimates of  billion during the same period in the previous year the company posted  eps the firm’s revenue was up  compared to the same quarter last year on average equities research analysts predict that zoetis inc will post  eps for the current year the company also recently announced a quarterly dividend which will be paid on friday september st investors of record on thursday june th will be given a  dividend this represents a  dividend on an annualized basis and a yield of  the exdividend date is tuesday june th zoetis’s payout ratio is  copyright violation notice this news story was first posted by daily political and is owned by of daily political if you are reading this news story on another site it was illegally stolen and reposted in violation of united states and international copyright laws the legal version of this news story can be read at httpswwwdailypoliticalcomzoetisincnyseztssharessoldbyboussardgavaudaninvestmentmanagementllphtml zts has been the topic of several research reports zacks investment research raised zoetis from a “hold” rating to a “buy” rating and set a  price target on the stock in a research note on wednesday may th jefferies group llc upped their price target on zoetis from  to  and gave the company a “buy” rating in a research note on tuesday may th bmo capital markets reaffirmed a “buy” rating and set a  price target on shares of zoetis in a research note on thursday may th argus reaffirmed a “buy” rating and set a  price target up previously from  on shares of zoetis in a research note on tuesday may th finally cl king initiated coverage on zoetis in a research note on friday may th they set a “buy” rating and a  price target on the stock one equities research analyst has rated the stock with a sell rating five have issued a hold rating and thirteen have given a buy rating to the company zoetis has an average rating of “buy” and a consensus target price of  in related news insider catherine a knupp sold  shares of the business’s stock in a transaction dated friday may th the stock was sold at an average price of  for a total value of  following the completion of the sale the insider now directly owns  shares of the company’s stock valued at approximately  the sale was disclosed in a filing with the securities  exchange commission which is accessible through this link insiders own  of the company’s stock about zoetis zoetis inc is engaged in the discovery development manufacture and commercialization of animal health medicines and vaccines with a focus on both livestock and companion animals the company has a business commercializing products across eight core species cattle swine poultry sheep and fish collectively livestock and dogs cats and horses collectively companion animals and within five product categories antiinfectives vaccines parasiticides medicated feed additives and other pharmaceuticals want to see what other hedge funds are holding zts visit holdingschannelcom to get the latest f filings and insider trades for zoetis inc nysezts receive news  ratings for zoetis inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for zoetis inc and related companies with marketbeatcoms free daily email newsletter  comment on this post click here to cancel reply name required mail will not be published required website wordpress hashcash needs javascript to work but your browser has javascript disabled your comment will be deleted latest news jeff sessions spoke of resigning after tensions increase with trump president trump’s tweets complicate already complicated week world leaders very critical of paris agreement decision by trump aide to president trump resigns with more expected scudclass missile launched by north korea  dailypolitical llc  all rights reserved privacy policy  about  columnists  contact insider trading  knupp catherine a  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  knupp catherine a select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view exercise  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view tax withholding  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view exercise  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view exercise  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view tax withholding  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view exercise  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view exercise  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view tax withholding  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view exercise  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  am nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  am nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  am nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  am nana zoetis inc zts knupp catherine aexecutive vice president   direct view option award  am nana zoetis inc zts knupp catherine aexecutive vice president   direct view exercise  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view tax withholding  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view exercise  pm nana zoetis inc zts knupp catherine aexecutive vice president   direct view   secformcom all rights reserved archives        tue  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  compensation information for catherine a knupp  executive vice president and president of rd of zoetis inc  salarycom enterprise small business personal contact us log in salaries jobs education advice catherine a knupp executive compensation as executive vice president and president of rd at zoetis inc catherine a knupp made  in total compensation of this total  was received as a salary  was received as a bonus  was received in stock options  was awarded as stock and  came from other types of compensation this information is according to proxy statements filed for the  fiscal year enter an executive or company name new search go the chart on this page features a breakdown of the total annual pay for catherine a knupp  executive vice president and president of rd at zoetis inc as reported in their proxy statements total cash compensation information is comprised of yearly base pay and bonuses zoetis inc income statements for executive base pay and bonus are filed yearly with the sec in the edgar filing system zoetis inc annual reports of executive compensation and pay are most commonly found in the def a documents total equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year other compensation covers all compensationlike awards that dont fit in any of these other standard categories numbers reported do not include change in pension value and nonqualified deferred compensation earnings other executives at this company kristin c peck clinton a lewis jr juan ramón alaix paul s herendeen glenn c david catherine a knupp base pay bonus  incentive comp total cash compensation stock award value option award value total equity total other total compensation browse executives by first name a b c d e f g h i j k l m n o p q r s t u v w x y z browse companies by company name a b c d e f g h i j k l m n o p q r s t u v w x y z  this report is not for commercial use thorough reviews have been conducted to assure this data accurately reflects disclosures however for a complete and definitive understanding of the pay practices of any company users should refer directly to the actual complete proxy statement use of data  disclaimer the information shown here is a reporting of information included in the companys proxy statement the proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information for those interested in conducting a detailed compensation analysis we recommend that you review the entire proxy statement you may retrieve the full proxy statement by going to the securities and exchange commission sec website at wwwsecgov and entering the companys name and then looking in the first column for an entry of form def a or any similar code you may also find the annual proxy statement by going directly to the companys website what is a proxy statement a proxy statement or proxy is a form that every publicly traded us company is required to file with the us securities  exchange commission sec within  days after the end of its fiscal year the proxy must be sent to every shareholder in advance of the companys annual shareholders meeting all proxy statements are public filings made available to the general public by the sec the proxy statements main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting including decisions such as electing directors ratifying the selection of auditors and other shareholderrelated decisions including shareholderinitiated initiatives also proxies must disclose specific detailed information regarding the pay practices for certain executives       privacy policy terms of use about us contact us  salarycom all rights reserved us salaries canadian salaries purchase a salary report salaries by category salaries by income salaries by industry popular salaries negotiation tips benefits calculator search job openings job openings by state job openings by category education by career education by level education by major cost of living calculator